2-4-dinitrofluorobenzene-sulfonic-acid and Breast-Neoplasms

2-4-dinitrofluorobenzene-sulfonic-acid has been researched along with Breast-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for 2-4-dinitrofluorobenzene-sulfonic-acid and Breast-Neoplasms

ArticleYear
Dynamic network biomarker to determine the critical point of breast cancer stage progression.
    Breast cancer (Tokyo, Japan), 2023, Volume: 30, Issue:3

    The discovery of early warning signs and biomarkers in patients with early breast cancer is crucial for the prevention and treatment of breast cancer. Dynamic Network Biomarker (DNB) is an approach based on nonlinear dynamics theory, which we exploited to identify a set of DNB members and their key genes as early warning signals during breast cancer staging progression.. First, based on the gene expression profile of breast cancer in the TCGA database, the DNB algorithm was used to calculate the composite index (CI) of each gene cluster in the process of breast cancer anatomical staging. Then we calculated gene modules associated with the clinical phenotype stage based on weighted gene co-expression network analysis (WGCNA), combined with DNB membership to identify key genes in the network.. We identified a set of gene clusters with the highest CI in Stage II as DNBs, whose roles in related pathways indicate the emergence of a tipping point and impact on breast cancer development. In addition, analysis of the key gene GPRIN1 showed that high expression of GPRIN1 predicts poor prognosis, and related immune analysis showed that GPRIN1 is involved in the development of breast cancer through immune aspects.. The discovery of DNBs and the key gene GPRIN1 can provide potential biomarkers and therapeutic targets for breast cancer.

    Topics: Biomarkers; Biomarkers, Tumor; Breast Neoplasms; Dinitrofluorobenzene; Female; Gene Expression Profiling; Humans

2023
Dual-Activated Nano-Prodrug for Chemo-Photodynamic Combination Therapy of Breast Cancer.
    International journal of molecular sciences, 2022, Dec-10, Volume: 23, Issue:24

    Herein, we developed a dual-activated prodrug, BTC, that contains three functional components: a glutathione (GSH)-responsive BODIPY-based photosensitizer with a photoinduced electron transfer (PET) effect between BODIPY and the 2,4-dinitrobenzenesulfonate (DNBS) group, and an ROS-responsive thioketal linker connecting BODIPY and the chemotherapeutic agent camptothecin (CPT). Interestingly, CPT displayed low toxicity because the active site of CPT was modified by the BODIPY-based macrocycle. Additionally, BTC was encapsulated with the amphiphilic polymer DSPE-mPEG

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Nanoparticles; Photochemotherapy; Photosensitizing Agents; Prodrugs; Reactive Oxygen Species

2022